Previous 10 | Next 10 |
home / stock / soltf / soltf news
2023-05-12 08:30:19 ET Sosei Group press release ( OTCPK:SOLTF ): Q1 GAAP EPS of -¥17.11. Revenue of ¥943M (-15.8% Y/Y). Outlook: At present, the Group has a strong cash runway into 2025 to fund its R&D activities. Our cost estimates and key initiati...
Tokyo, Japan and Cambridge , UK, 12 May 20 2 3 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023. The full report can b...
Eiko Tomita, Vice President, Global Regulatory Affairs at Bristol Myers Squibb , elected to the Company’s Board of Directors Candelle Chong promoted to Executive Vice President and Chief of Staff , previously Senior Vice President , Corporate Strategy ...
Tokyo, Japan and Cambridge, UK, 15 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, today announces it has changed the market on which the C...
Tokyo, Japan and Cambridge , UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, is pleased to announce it has received appro...
Sosei Group press release ( OTCPK:SOLTF ): FY GAAP EPS of ¥4.63. Revenue of ¥15.57B (-12.1% Y/Y). A financial results forecast for the year ended December 31, 2023 has not been provided because it is difficult to forecast a reasonable estimate of the full-year ...
Tokyo, Japan and Cambridge , UK, 14 February 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, provides an update on operational activi...
TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, will announce its earnings results and present...
TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero Bio Phase 1 study in healthy volunteers expected to begin in Q1 2023 with support from a US$5.3M gra...
Sosei Group press release (OTCPK:SOLTF): Q1 GAAP EPS of -¥25.39. Revenue of $9.6M (+433.3% Y/Y). For further details see: Sosei Group GAAP EPS of -¥25.39, revenue of $9.6M
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on Friday, 9 August 2024. The Company will host a live webinar presentation with C...
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million...
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance (ESG) Report for the year ended 31 December 2023. The Annu...